Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SAN DIEGO, Feb. 08, 2016 -- SENTÉ, a privately held specialty aesthetics company pioneering the development of differentiated medical grade skincare products based on the science of glycosaminoglycans, today announced the close of a $5 million financing. This financing included both existing and new individual investors and provides SENTÉ with a sizable cash balance to fuel expansion and continued company growth.
“We are very pleased to continue seeing such strong investor interest in our company from leading experts in the healthcare and aesthetic field,” said Kleanthis G. Xanthopoulos, Ph.D., SENTÉ Co-Founder and Board Member. “Our investors share our vision in creating unique science based dermatological products that will have profound impacts on the skin, and we very much look forward to continued growth in this endeavor."
The Company, which realized top line year over year growth of 266%, will use this financing to increase its domestic sales force, support the launch of new and innovative products, pursue international expansion and invest behind meaningful new technologies.
“We are excited about the significant progress SENTÉ made in 2015 and we are equally pleased with the continued financial support of our investors,” said Faheem Hasnain, Chairman of the Board of SENTÉ. “We look forward to an exciting year in 2016 with continued strong revenue growth.”
About SENTÉ:
SENTÉ is a privately held specialty aesthetics company leveraging its expertise and foundation in biotechnology to deliver novel, science-based skin care products. SENTÉ is a recognized leader in the development of innovative and targeted medical skincare products based on glycosaminoglycans. Founded in 2007 and based in San Diego, California, further information may be found at http://sentelabs.com/. SENTÉ products are available through our exclusive network of physicians and medically supervised spas.
Financial Contact: Michael Brower Chief Financial Officer [email protected] p: 760.478.3603 Media Contact: Creative Media Marketing Danielle Hale [email protected] p: 212.979.8884 ext. 213
